President Donald Trump said Monday he's in no rush to respond to a coordinated attack that hit Saudi Arabia's oil industry over the weekend.Marketsread more
The price of oil could go sharply higher, depending on the duration of the disruption at Saudi oil facilities and whether there is a military response.Powering the Futureread more
Energy stocks, one of the worst-performing sectors this year, spiked Monday after an attack on Saudi Arabia's heart of oil production Saturday sent oil prices soaring.Marketsread more
The Saudi-led military coalition battling Yemen's Houthi movement said on Monday that the attack on Saudi oil plants was carried out by Iranian weapons and did not originate...Oilread more
"The United States military, with our interagency team, is working with our partners to address this unprecedented attack and defend the international rules-based order that...Politicsread more
Crude oil's spike following attacks on Saudi Arabia's energy supply has experts weighing whether or not the gains will last.ETF Edgeread more
Traders in the fed funds futures market on Monday were pricing in a 34% chance that the Fed will stay put on rates.The Fedread more
Gas prices could rise by about 20 cents per gallon "starting tomorrow," oil analyst Andy Lipow says Monday.Oil and Gasread more
Some operators are cashing in on the CBD craze by substituting cheap and illegal synthetic marijuana for natural CBD in vapes and edibles such as gummy bears, an AP...Health and Scienceread more
Attack on Saudi oil facilities shows that 'risk is real', Chevron CEO Michael Wirth said on CNBC's "Closing Bell" Monday.Marketsread more
J.P. Morgan's chief quant says oil prices would start to hurt stock prices when they hit the $80 to $85 range.Market Insiderread more
Shares of Tesaro jumped 19 percent on Monday after the company announced positive results for its Phase 3 clinical trial drug niraparib, a potential treatment for ovarian cancer. As a result, Merrill Lynch upgraded its rating on the stock from "neutral" to "buy."
Tesaro shared that when niraparib was tested in combination with chemotherapy treatment, it found the drug extended progression-free survival, according to a statement made on Monday. Niraparib is part of a class of new medicines called PARP inhibitors.
"These landmark results are extremely encouraging for the ovarian cancer community," said Dr. Mansoor Raza Mirza, medical director of the Nordic Society of Gynecologic Oncology, in the statement. "The effectiveness of platinum-based chemotherapy diminishes over time, and PFS [progression-free survival] and platinum-free intervals generally become shorter after each round of platinum treatment."
Clovis, another oncology-focused biopharmaceutical company developing a drug for ovarian cancer, also saw its shares climb more than 10 percent on Monday.